Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

The biggest buzz around GLP-1 drugs these days has nothing to do with weight loss. And that might lead to some problems for ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared to those on other medications.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Some popular weight loss drugs — such as Ozempic, Mounjaro and Wegovy — may lower the risk of dementia and stroke for patients with Type 2 diabetes and obesity, new research suggests.

Ozempic Might Be a Dementia Buster, Too Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people’s risk of dementia.

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...